ReviewCurrent pharmaceutical design2011
Mitochondrial therapeutics for cardioprotection.
Review in Current pharmaceutical design, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Mechanistic investigation of the ameliorative effect of liquiritin on hypoxia/reoxygenation‑induced cardiomyocyte injury based on network pharmacology andExperimental and therapeutic medicine · 2024Article
- PMCardiovascular toxicology · 2022Article
- The dynamin-related protein 1 is decreased and the mitochondrial network is altered in Friedreich's ataxia cardiomyopathy.The international journal of biochemistry & cell biology · 2022Article
- Article
- Toxicokinetics of Arenobufagin and its Cardiotoxicity Mechanism Exploration Based on Lipidomics and Proteomics Approaches in Rats.Frontiers in pharmacology · 2021Article
- Targeting Cardiac Metabolic Pathways: A Role in Ischemic Management.Vascular health and risk management · 2020Review
- The Role of Mitochondria in the Mechanisms of Cardiac Ischemia-Reperfusion Injury.Antioxidants (Basel, Switzerland) · 2019Review
- Reference Intervals of Mitochondrial DNA Copy Number in Peripheral Blood for Chinese Minors and Adults.Chinese medical journal · 2017Article
- Redox biology and the interface between bioenergetics, autophagy and circadian control of metabolism.Free radical biology & medicine · 2016Review
- Mitochondrial Metabolism in Aging Heart.Circulation research · 2016Review
- Chemerin-induced mitochondrial dysfunction in skeletal muscle.Journal of cellular and molecular medicine · 2015Article
- Article
- Sevoflurane postconditioning protects rat hearts against ischemia-reperfusion injury via the activation of PI3K/AKT/mTOR signaling.Scientific reports · 2014Article
- Proteostasis and the aging proteome in health and disease.The journals of gerontology. Series A, Biological sciences and medical sciences · 2014Review
- Article
- Integration of cellular bioenergetics with mitochondrial quality control and autophagy.Biological chemistry · 2012Review
- Protein Kinase Signaling at the Crossroads of Myocyte Life and Death in Ischemic Heart Disease.Drug discovery today. Therapeutic strategies · 2012Article
- Labdane diterpenes protect against anoxia/reperfusion injury in cardiomyocytes: involvement of AKT activation.Cell death & disease · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Mitochondria represent approximately one-third of the mass of the heart and play a critical role in maintaining cellular function-however, they are also a potent source of free radicals and pro-apoptotic factors. As such, maintaining mitochondrial homeostasis is essential to cell survival. As the dominant source of ATP, continuous quality control is mandatory to ensure their ongoing optimal function. Mitochondrial quality control is accomplished by the dynamic interplay of fusion, fission, autophagy, and mitochondrial biogenesis. This review examines these processes in the heart and considers their role in the context of ischemia-reperfusion injury. Interventions that modulate mitochondrial turnover, including pharmacologic agents, exercise, and caloric restriction are discussed as a means to improve mitochondrial quality control, ameliorate cardiovascular dysfunction, and enhance longevity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.